Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that most pediatric dermatologists prefer class 1 and 2 topical corticosteroids as first-line treatments for pediatric alopecia areata, with increasing use of JAK inhibitors as second-line therapy.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

This study confirmed that the Alopecia Areata-Investigator Global Assessment and other clinical outcome assessments are valid and relevant measures of treatment success for alopecia areata patients in Japan, aligning with previous North American findings.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study found that alopecia areata often affects beard hair as frequently as scalp hair, leading the authors to propose a new scoring system and a subtype called alopecia subuniversalis for extensive hair involvement.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.

In this study, intravenous corticosteroid pulse therapy for rapidly progressive alopecia areata showed that 74.5% of patients achieved a good response in the long-term, and a revised scoring system predicted relapse risk effectively in cases with preceding infectious symptoms.

This study reports that topical immunotherapy with SADBE and DPCP is the most effective short-term treatment for hair regrowth in children with severe alopecia areata compared to other treatments.

This study observed greater clinical improvement in patients with alopecia areata who received individualized homoeopathic constitutional treatment compared to those who received Acid Phos, but further research with objective measures is needed to confirm these findings.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This case report describes a patient with both rheumatoid arthritis and alopecia areata who showed improvement in both conditions after treatment with baricitinib monotherapy, highlighting the importance of personalized treatment approaches in managing co-occurring autoimmune diseases.

The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.

Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

In this study, researchers analyzed dermatologists' treatment practices for alopecia areata across five European countries, finding that topical and intralesional corticosteroids are most commonly prescribed for mild to moderate cases, while severe cases often see increased use of immunosuppressants and wigs.

This study observed that patients with AA showed a high willingness to trade off lifespan for better disease-specific quality of life, indicating a significant disease burden.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This case report highlights that Baricitinib led to significant hair regrowth and resolution of atopic dermatitis symptoms in a 22-year-old female with coexisting autoimmune conditions.

This article reviews the clinical features of dermatopathia pigmentosa reticularis, highlighting its characteristic triad of symptoms, but provides no new research results.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.